Summary
- Mayer Brown has advised SERB Pharmaceuticals on a significant agreement to acquire exclusive rights for Idefirix® (Imlifidase) from Hansa Biopharma AB in Europe and the MENA region.
- The acquisition includes development and commercialization rights across multiple countries, including the EU, UK, and Switzerland.
- Idefirix® is aimed at desensitizing highly sensitized adult patients awaiting kidney transplants, addressing urgent medical needs.
- The transaction awaits customary foreign direct investment regulatory approval, expected to finalize within 60 days.
Join the discussion — sign up to comment, upvote, and save articles.